Amicus Therapeutics, Inc.
FOLD
株式のランク
#3689
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
株価
$14.49
最終同期: 2026-04-27
時価総額
$4.55B
変化（1日）
0.00%
変化（1年）
71.68%
国
US
取引 Amicus Therapeutics, Inc. (FOLD)
カテゴリー
Healthcare
Amicus Therapeutics, Inc.（FOLD）のP/B比率
October 2026 時点のP/B比率 TTM: 16.33
Amicus Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 16.33 です。2023 年末時点でのP/B比率は 26.15 でした。
Amicus Therapeutics, Inc. の P/B 比率の履歴（2003 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 16.33 | 10.47% |
| 2024 | 14.78 | -43.49% |
| 2023 | 26.15 | -8.84% |
| 2022 | 28.68 | 181.23% |
| 2021 | 10.20 | -51.13% |
| 2020 | 20.87 | 324.64% |
| 2019 | 4.92 | -5.30% |
| 2018 | 5.19 | -17.01% |
| 2017 | 6.25 | 237.21% |
| 2016 | 1.85 | -39.50% |
| 2015 | 3.07 | -39.53% |
| 2014 | 5.07 | 92.44% |
| 2013 | 2.63 | 49.32% |
| 2012 | 1.76 | -56.10% |
| 2011 | 4.02 | 100.18% |
| 2010 | 2.01 | 60.55% |
| 2009 | 1.25 | -50.51% |
| 2008 | 2.53 | 83.43% |
| 2007 | 1.38 | -1,105.40% |
| 2006 | -0.14 | -17.07% |
| 2005 | -0.17 | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | -0.84 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -61.72% |
US
|
|
| 13.2547 | -18.82% |
US
|
|
| 4.208 | -74.23% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -62.14% |
NL
|
